Chemesis International Inc. Announces Brand Partnership with Ubican Global

Ubican brings well-known brands and is a trusted vendor with an established sales and marketing program.

VANCOUVER, BC / December 3, 2020 / Chemesis International Inc. (CSE:CSI.U) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces Ubican Global (“Ubican”) as its primary supplier for its United States VICKI program. Ubican is a trusted supplier of a family of brands, each with multiple types of products. The products include tinctures, digestibles, edibles, pet, beauty/skincare, topical, edible, fitness, and smokable products.

The team has carefully cultivated over 10+ brands that are now recognized throughout the CBD industry. Each brand has a specific tailored approach for its demographic, which allows brands to build brand loyalty and reoccurring revenues.

Bryce Davis, CEO of Ubican remarked. “Ubican’s focus is to bring high-quality and diversified brands and products to the marketplace. The scope of our portfolio allows us to cater to a wide variety of demographics, which fits well with the VICKI program. As retail and consumer habits continue to evolve, we are enthusiastic about providing our consumers the ability to interact with the VICKI platform. We are excited about our partnership with Chemesis and look forward to jointly building both brands in the US market.”

Chemesis will work with Ubican to place VICKI machines in high traffic areas that can help build consistent revenues. The teams will work in tandem to ensure each VICKI is stocked with a specific set of brands and products that support the demographic.

“Partnering with Ubican is a significant step forward in our development program for the VICKI sales strategy, the team provides a strong and robust set of brands and products,” said President of Chemesis, Josh Rosenberg. “With the support of Ubican as our primary supplier, Chemesis will apply to ensure a consistent supply of high quality products for our VICKI machines across the U.S.”


On Behalf of The Board of Directors
Josh Rosenberg

About Chemesis International Inc.

Chemesis focuses on prudent capital allocations to ensure it maintains second mover advantage as it enters new markets with a proven lift & shift consumer focused model deployed with the objective a being #1 or a strong #2 in every market in which we compete. Chemesis leverages a portfolio of strong consumer brands to recruit, retain, & grow share of wallet with a proven consumer loyalty platform. Chemesis is focused on scalable growth within our business operations through disciplined investment of both insource and outsourced levers to maximize use of capital. This includes our retail strategy of coalescing dispensary and alternative route to market.

Chemesis and its team are committed to building a strong unattended and attended retail model for the cannabis market across the United States and Puerto Rico. Chemesis’ retail brand, Green Spirit Rx, will continue to provide consumers with industry-leading technology, the most sought-after products and continued education.  

Investor Relations:
1 (604) 398-3378

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the ability of the Company to continue to operate under the Licenses, and the ability of the Company to engage in any administrative process with the Department of Health.  Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements including, among other things, the risks that the Company will not be able to maintain or continue licensed activities under the Licences as currently being conducted, or at all, and that the Company’s products and plans will vary significantly as a result, and that the Company will not be permitted to engage with the Department of Health through an administrative or other process to address the concerns raised. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release


Sign me up for News Alerts!